Kardium opens Globe registry to track outcomes after commercial launch

Kardium said in its October 21 announcement that Overlake Medical Center in Bellevue, Washington, activated the first Globe Registry site and enrolled its first patient. Participants will be followed for 12 months, starting evidence collection on the cardiac mapping and pulsed field ablation system in routine practice.

Globe combines high-density mapping and ablation in one catheter. CEO Kevin Chaplin and Overlake electrophysiology director Maheer Gandhavadi described encouraging early experience, but the announcement supplies no numerical outcomes supporting those observations. The single-arm observational design can document outcomes among treated patients; it cannot establish superiority over another system.

Evidence gathering accompanies manufacturing expansion. In its August funding announcement, Kardium reported federal support of up to $31.25 million toward a $125 million Vancouver project. That commitment concerns production capacity, not demonstrated clinical performance.

For electrophysiology leaders and medical-device investors, the next evidence is reported safety and 12-month effectiveness results, alongside confirmed Canadian participation. The registry record predates enrollment and still says “not yet recruiting”; the October announcement names only the Washington site.

Illustration generated with AI using Ollama. It does not depict a Kardium facility or the Globe device.